Precision BioSciences Inc (DTIL)
Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on gene editing therapies in the United States. The company’s ARCUS genome editing platform is designed to support DNA insertion, removal, and repair, and underpins a development pipeline aimed at in vivo gene editing applications. Its programs include PBGENE-HBV for chronic hepatitis B, PBGENE-DMD (Excision) for Duchenne muscular dystrophy, PBGENE-3243 for m.3243-associated mitochondrial diseases, and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. Precision BioSciences also has collaboration agreements with TG Cell Therapy, Inc. and iECURE, Inc. to advance ARCUS-based gene editing and insertion programs. Incorporated in 2006, the company is headquartered in Durham, North Carolina.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DTIL
|
$5.73
|
-20.3% Downside
|
Overvalued
|
$29.40
|
308.9% Upside
|
Bargain
|
Fair
|
0.0%
|
November 10, 2026
|
4.0x
|
4.0x
|
198.5 M
|
120 M
|
13.3%
|
92.2%
|
-4.9
|
96.9%
|
